Daoxiang Wu
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera.
Journal: Leukemia & lymphoma
Published: July 17, 2026
Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.
Journal: Current hematologic malignancy reports
Published: July 16, 2025
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.
Journal: Pharmacology research & perspectives
Published: September 24, 2024
Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b.
Journal: British journal of haematology
Published: August 15, 2024
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.
Journal: Frontiers in pharmacology
Published: June 27, 2024
Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
Journal: British journal of clinical pharmacology
Published: December 06, 2023
A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
Journal: Future oncology (London, England)
Published: May 02, 2023
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
Journal: Experimental hematology & oncology
Published: March 29, 2023
Showing 1-10 of 10
Last Updated: 09/26/2026